Proposed Method for Measuring the LET of Radiotherapeutic Particle Beams Stephen D
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Radiation Therapy
Radiation Therapy Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation. • One person in three will develop some form of cancer in their lifetime. • One person in five will die from that cancer. • Cancer is the second leading cause of death but exceeds all other diseases in terms of years of working-life lost. Diagrammatic representation of a Image removed. slice through a large solid tumor. From Webster’s Medical Dictionary: Cancer – A malignant tumor of potentially unlimited growth that expands locally by invasion and sytemically by metastasis. Tumor – an abnormal mass of tissues that arises from cells of pre-existent tissue, and serves no useful purpose. Malignant – dangerous and likely to be fatal (as opposed to “benign,” which refers to a non-dangerous growth). 1 Unlimited Growth: • Cancer cells multiply in an unregulated manner independent of normal control mechanisms. • Formation of a solid mass in organs. • Multiplication of bone marrow stem cells gives rise to leukemia, a cancer of the blood. Image removed. Solid tumors: • Primary tumor may be present in the body for months or years before clinical symptoms develop. • Some tumors can be managed and the patient often cured provided there has been no significant invasion of vital organs. • Patients do not often die of primary tumors---brain tumors are the exception. Metastases: • The spread of tumor cells from one part of the body to another, usually by the blood or lymph systems. • Metastases are more usually the cause of death. • Metastases are especially common in the bone marrow, liver, lungs and brain. -
30. Radioactivity and Radiation Protection 1 30
30. Radioactivity and radiation protection 1 30. RADIOACTIVITY AND RADIATION PROTECTION Revised August 2011 by S. Roesler and M. Silari (CERN). 30.1. Definitions [1,2] 30.1.1. Physical quantities : • Fluence, Φ (unit: 1/m2): The fluence is the quotient of dN by da, where dN is the number of particles incident upon a small sphere of cross-sectional area da Φ = dN/da . (30.1) In dosimetric calculations, fluence is frequently expressed in terms of the lengths of the particle trajectories. It can be shown that the fluence, Φ, is given by Φ = dl/dV, where dl is the sum of the particle trajectory lengths in the volume dV . • Absorbed dose, D (unit: gray, 1 Gy=1 J/kg=100 rad): The absorbed dose is the energy imparted by ionizing radiation in a volume element of a specified material divided by the mass of this volume element. • Kerma, K (unit: gray): Kerma is the sum of the initial kinetic energies of all charged particles liberated by indirectly ionizing radiation in a volume element of the specified material divided by the mass of this volume element. • Linear energy transfer, L or LET (unit: J/m, often given in keV/µm): The linear energy transfer is the mean energy, dE, lost by a charged particle owing to collisions with electrons in traversing a distance dl in matter. Low-LET radiation: x rays and gamma rays (accompanied by charged particles due to interactions with the surrounding medium) or light charged particles such as electrons that produce sparse ionizing events far apart at a molecular scale (L < 10 keV/µm). -
Ionoacoustic Bragg Peak Localization for Charged Particle Cancer Therapy
Ionoacoustic Bragg Peak Localization for Charged Particle Cancer Therapy Siavash Yousefi, December-9-2015 Jonathan Alava, 7 Roberts Proton Therapy Center in Philadelphia Cancer Treatment: Protons vs. X-ray Superior Dose Distribution Photon vs. Proton Dose Distribution http://www.wikiwand.com/en/Particle_therapy Knopf, Antje-Christin, and Antony Lomax. "In vivo proton range verification: a review." Physics in medicine and biology 58.15 (2013): R131. Proton and Carbon Therapy Facilities Carbon Therapy Facilities PROTON THERAPY FACILITIES External Beam LINAC External Beam LINAC Proton Therapy Facility : C Heidelberg Ion Therapy Center 60m x 70m Compact Design Uncertainties in Proton Therapy • Due to sharp dose fall-off at Bragg peak • Protons are more sensitive to uncertainties than photon • Damaging surrounding healthy tissue/not treating tumor Sources of uncertainties • Stochastic error (CT noise) • CT artifacts • CT resolution (partial volume effect) • Hounsfield unit (HU) conversion method Proton Range Verification Techniques Measurement technique › Direct › Indirect: range is implied from another signal Timing › Online: during treatment delivery › Offline: performed after completion of the treatment Direct Indirect Prompt gamma imaging (3D) Range probes PET imaging (3D) Online Proton radiography Ionoacoustic PET imaging (3D) Offline MRI (3D) PET Imaging for Range Verification • Protons and heavy ions cause nuclear fragmentation reactions • Generation of positron emitting isotopes (15O, 11C) • PET scan measures the distribution of activities • Clinically appealing; no additional dose to the patient PET Verification of Proton Therapy: Operational Modalities In-beam PET Offline PET In-room PET PET Verification Studies in Patient Clival chordoma receiving a posterior–anterior followed by a lateral field ~26 min (T1) and 16 min (T2) after completion. -
Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy"
Report Technical Meeting on "Alpha emitting radionuclides and radiopharmaceuticals for therapy" June, 24−28, 2013 IAEA Headquarters, Vienna, Austria 1 BACKGROUND An alpha (α)-particle is a ionised 4He nucleus with a +2 electric charge and, therefore, it is relatively heavier than other subatomic particles emitted from decaying radionuclides such as electrons, neutrons, and protons. Because of this physical properties, α-particles are more effective ionization agents with linear energy transfer (LET) of the order of magnitude of 100 keV/µm, and are highly efficient in depositing energy over a short range in tissue (50–100 µm). Actually, a α-particle deposits 1500 times more energy per unit path length than a β- particle. The high mean energy deposition in tissues gives α-radiation exquisite cytotoxicity, which commonly manifests itself within the range of cell’s dimensions. This high LET may allow for an accurately controlled therapeutic modality that can be targeted to selected malignant cells with negligible burden to normal tissues. The short path length renders α-emitters suitable for treatment of minimal disease such as micro metastases or residual tumour after surgical resection of a primary lesion, hematologic cancers, infections, and compartmental cancers. A highly desirable goal in cancer therapy is the ability to target malignant cells while sparing normal cells. If significant differential targeting is achieved by a radiolabelled vector specifically designed to hold onto cancer cells, then a toxic payload on the vector will deliver a lethal dose preferentially to those cells expressing higher concentrations of the target molecule. This could be achieved by using highly cytotoxic α-particle radiation carried to specific sites of cancer cells by appropriate vectors. -
Stereotactic Radiosurgery with Charged-Particle Beams: Technique and Clinical Experience
Review Article Stereotactic radiosurgery with charged-particle beams: technique and clinical experience Richard P. Levy1, Reinhard W. M. Schulte2 1Advanced Beam Cancer Treatment Foundation, 887 Wildrose Circle, Lake Arrowhead, CA 92352-2356 USA; 2Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, 92354, USA Corresponding to: Richard Levy, MD, PhD. PO Box 2356, Lake Arrowhead, CA 92352-2356 USA. Email: [email protected]. Abstract: Stereotactic radiosurgery using charged-particle beams has been the subject of biomedical research and clinical development for almost 60 years. Energetic beams of charged particles of proton mass or greater (e.g., nuclei of hydrogen, helium or carbon atoms) manifest unique physical and radiobiological properties that offer advantages for neurosurgical application and for neuroscience research. These beams can be readily collimated to any desired cross-sectional size and shape. At higher kinetic energies, the beams can penetrate entirely through the patient in a similar fashion to high-energy photon beams but without exponential fall-off of dose. At lower kinetic energies, the beams exhibit increased dose-deposition (Bragg ionization peak) at a finite depth in tissue that is determined by the beam’s energy as it enters the patient. These properties enable highly precise, 3-dimensional placement of radiation doses to conform to uniquely shaped target volumes anywhere within the brain. Given the radiosurgical requirements for diagnostic image acquisition and fusion, precise target delineation and treatment planning, and millimeter- or even submillimeter-accurate dose delivery, reliable stereotactic fixation and immobilization techniques have been mandatory for intracranial charged particle radiosurgery. Non-invasive approaches initially used thermoplastic masks with coordinate registration made by reference to bony landmarks, a technique later supplemented by using vacuum-assisted dental fixation and implanted titanium fiducial markers for image guidance. -
August 31, 1963 NATURE 923
No. 4896 August 31, 1963 NATURE 923 RADIOBIOLOGY missed, as Berry, Oliver and Porter seem to suggest, though their imputation that cost is our sole consideration A Fast-neutron Source for Radiotherapy is, of course, incorrect. IN a recent note, Lomer and Greene1 have recommended It is perhaps worth enlarging a little on the importance the development of a 14-MeV fast-neutron source for of compactness. In radiotherapy accurate direction of the radiotherapy. We feel that there are disadvantages to beam at the tumour is a primary consideration, and this is this approach. The relative biological effectiveness of best achieved by using a flexibly mounted radiation source fast neutrons is related to their linear energy transfer, so that the beam may be moved with respect to a com which in turn varies inversely with the energy of the fortably placed patient, rather than the patient 'lined up' neutron•,•. It has been shown that cell-killing by 1-2- to the machine: compactness is thus important because it facilitates MeV neutrons (linear energy transfer, 50-60 keV/µ) is accurate treatment. relatively independent of oxygen•. As the energy of the We are, of course, well aware that designing a neutron neutrons is increased, the effect becomes more oxygen collimator is a problem, and the solution of this problem dependent•-30-MeV neutrons would have a linear energy is naturally an important part of our development pro gra,mme. transfer similar to 250-kV X-rays, and hence a similar oxygen-dependence. Tf one is to expect an improvement Furthermore, even if 14-MeV neutrons prove to have no in the results of radiotherapy due to the relative oxygen biological advantage over megavoltage X-rays, the D-T source independence of the effect of fast neutrons, then one must may still be competitive with high-energy X-ray units, attempt to use those neutrons the effects of which are in so far as there are reasonable grounds for believing relatively oxygen-independent; this cannot be claimed that they will produce similar dose distributions inside a patient. -
Dose Reporting in Ion Beam Therapy
IAEA-TECDOC-1560 Dose Reporting in Ion Beam Therapy Proceedings of a meeting organized jointly by the International Atomic Energy Agency and the International Commission on Radiation Units and Measurements, Inc. and held in Ohio, United States of America, 18–20 March 2006 June 2007 IAEA-TECDOC-1560 Dose Reporting in Ion Beam Therapy Proceedings of a meeting organized jointly by the International Atomic Energy Agency and the International Commission on Radiation Units and Measurements, Inc. and held in Ohio, United States of America, 18–20 March 2006 June 2007 The originating Section of this publication in the IAEA was: Applied Radiation Biology and Radiotherapy Section International Atomic Energy Agency Wagramer Strasse 5 P.O. Box 100 A-1400 Vienna, Austria DOSE REPORTING IN ION BEAM THERAPY IAEA, VIENNA, 2007 IAEA-TECDOC-1560 ISBN 978–92–0–105807–2 ISSN 1011–4289 © IAEA, 2007 Printed by the IAEA in Austria June 2007 FOREWORD Following the pioneering work in Berkeley, USA, ion beam therapy for cancer treatment is at present offered in Chiba and Hyogo in Japan, and Darmstadt in Germany. Other facilities are coming close to completion or are at various stages of planning in Europe and Japan. In all these facilities, carbon ions have been selected as the ions of choice, at least in the first phase. Taking into account this fast development, the complicated technical and radiobiological research issues involved, and the hope it raises for some types of cancer patients, the IAEA and the International Commission on Radiation Units and measurements (ICRU) jointly sponsored a technical meeting held in Vienna, 23–24 June 2004. -
Α-Particle Emitters in Radioimmunotherapy: New And
INVITED COMMENTARY ␣-Particle Emitters in Radioimmunotherapy: New and Welcome Challenges to Medical Internal Dosimetry sulting in the release of the daughter as the cellular S value methodology to Over the past decade, there has a free element. include time-dependent partial contri- been progressively stronger interest in Two very different approaches can butions of the various daughter emis- the use of ␣-particle emitters for radio- be applied to the dosimetry of ␣-parti- sions in the serial decay chains of immunotherapy (1–6). With proper lo- cle emitters. One is microdosimetry, in 225Ac, 221At, 213Bi, and 223Ra. In their calization of the labeled antibody, the which the probabilistic nature of approach, a cutoff time (0) is selected high linear energy transfer of ␣-parti- ␣-particle emission and its trajectory before which free elemental daughter cles provides a correspondingly high through the cell and cell nucleus are radionuclides are considered to remain probability of mitotic cell kill when explicitly considered (1,8–10). In a in the same source configuration as compared with an equivalent number microdosimetric analysis, probability that assumed for the parent. At short of cellular traversals by lower linear density functions of specific energy are cutoff times, the daughter radionu- energy transfer -particles. Conse- obtained (stochastic expressions of en- clides, which are released as free ele- quently, much developmental work ergy imparted per unit mass to small ments after the ␣-decay of the parent, has been initiated in the production, targets), as well as frequencies of zero- diffuse or migrate far from the site of chemistry, and preclinical trials of can- dose contribution. -
Alpha Emitters for Radiotherapy: Basic Radiochemistry to Clinical Studies Part 1
Journal of Nuclear Medicine, published on March 15, 2018 as doi:10.2967/jnumed.116.186338 Alpha Emitters for Radiotherapy: Basic Radiochemistry to Clinical Studies _ Part 1 Running title: Alpha Emitters for Radiotherapy Sophie Poty1, Lynn C. Francesconi2,3, Michael R. McDevitt1,4, Michael J. Morris,5 Jason S. Lewis1,6 1Department of Radiology and the Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Department of Chemistry, Hunter College, New York, NY, USA 3The Graduate Center of the City University of New York, New York, NY, USA 4Departments of Radiology, Weill Cornell Medical College, New York, NY, USA 5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA 6Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, NY, USA Correspondence: Jason S. Lewis, PhD, 1275 York Avenue, New York, NY 10065, USA. Phone: 646-888-3038, FAX: 646-422-0408, Email: [email protected] First author: Sophie Poty, PhD, 1275 York Avenue, New York, NY 10065, USA. Phone: 646- 888-3080, FAX: 646-422-0408, Email: [email protected] Word count: 5317 Disclaimer: The authors have nothing to disclose. Financial support: The authors gratefully acknowledge the Radiochemistry and Molecular Imaging Probe core, which was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748. We gratefully acknowledge Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research and The Center for Experimental Therapeutics of Memorial Sloan Kettering Cancer Center (JSL) and the fellowship from the François Wallace Monahan Fellowship from the JLM Benevolent Fund (SP). -
RELATIVE BIOLOGICAL EFFECTIVENESS in ION BEAM THERAPY TECHNICAL REPORTS SERIES No
10.24 mm technical reportS series no. 46i This report covers all the aspects of the relative biological effectiveness (RBE) of ion beams, including laboratory measurements of RBE and the important variables that influence it, dose related quantities and units, and approaches to the clinical use of the concept of RBE based on experimental findings, theoretical models, and previous clinical experience with fast neutrons and ions. RBE is a simple concept but its clinical Technical Reports SeriEs No. 46i application is complex. Future developments in ion therapy will require a coherent approach to the reporting of therapies and their outcomes, not only for comparison with other ion facilities but also with conventional and newly developing photon irradiation techniques. The report is the result of a joint initiative between the IAEA and the International Commission on Radiation Relative Biological Units and Measurements, and is the only current extensive review of ion RBE. Relative Biological Effectiveness in Therapy Ion Beam Effectiveness in Ion Beam Therapy Jointly sponsored by the IAEA and ICRU INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA ISBN 978–92–0–107807–0 ISSN 0074–1914 07-32641_D461_CovI-IV.indd 1 2008-04-01 10:47:19 RELATIVE BIOLOGICAL EFFECTIVENESS IN ION BEAM THERAPY TECHNICAL REPORTS SERIES No. 461 RELATIVE BIOLOGICAL EFFECTIVENESS IN ION BEAM THERAPY JOINTLY SPONSORED BY THE INTERNATIONAL ATOMIC ENERGY AGENCY AND THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 2008 COPYRIGHT NOTICE All IAEA scientific and technical publications are protected by the terms of the Universal Copyright Convention as adopted in 1952 (Berne) and as revised in 1972 (Paris). -
Basic Physics of Proton Therapy
University of Florida Proton Therapy Institute Basic Physics of Proton Therapy Roelf Slopema overview I. basic interactions . energy loss . scattering . nuclear interactions II. clinical beams . pdd . lateral penumbra interactions / energy loss Primarily protons lose energy in coulomb interactions with the outer-shell electrons of the target atoms. • excitation and ionization of atoms • loss per interaction small ‘continuously slowing down’ • range secondary e+ <1mm dose absorbed locally • no significant deflection protons by electrons interactions / energy loss Energ y loss is given b y Bethe-Bloch equ ation: + corrections Tmax max energy transfer to free electron Tmax max energy transfer to free electron • to first order: –dE/dx 1/speed2 2 2 • max electron energy: Tmax 4Tm4 T mec /m/ mpc T=200 MeV Tmax 0.4 MeV range 1.4mm ….but most electrons far lower energy in practice we use range-energy tables and measured depth dose curves. Equations from Review of particle physics, C. Amsler et al., Physics Letters B667, 1 (2008) stopping power water stopping power water p+ 200MeV Bragg peak Bragg peak Bragg peak William Bragg W.H. Bragg and R. Kleeman, On the ionization curves of radium, Philosophical Magazine S6 (1904), 726-738 stopping power Graph based on NIST data interactions / scattering PiPrimaril y protons scatter d ue to el asti c coulomb interactions with the target nuclei. • many, small angle deflections • full description Moliere, gaussian approx. Highland p proton momentum L target thickness v proton speed LR target radiation length . 0 1/pv 1/(2*T) T<<938MeV -050.5 . material dependence: 0 1/LR 2 2 1 g/cm of water (LR =36.1 g/cm ) 0=5mrad for T=200MeV 2 2 1 g/cm of lead (LR = 6.37 g/cm ) 0=14mrad for T=200MeV Highland neglects large-angle tails, but works well in many situations… Equation from Gottschalk (Passive beam spreading) radial spread in water Approximation: 0.02 x range Calculation using Highland’s equation. -
The Biological Effects of Space Radiation During Long Stays in Space
Biological Sciences in Space, Vol.18 No.4 (2004):Ohnishi, 201-205 K. and Ohnishi, T. © 2004 Jpn. Soc. Biol. Sci. Space The Biological Effects of Space Radiation during Long Stays in Space Ken Ohnishi and Takeo Ohnishi Department of Biology, Nara Medical University School of Medicine,Shijo-cho 840, Kashihara, Nara 634-8521, Japan. Abstract Many space experiments are scheduled for the International Space Station (ISS). Completion of the ISS will soon become a reality. Astronauts will be exposed to low-level background components from space radiation including heavy ions and other high-linear energy transfer (LET) radiation. For long-term stay in space, we have to protect human health from space radiation. At the same time, we should recognize the maximum permissible doses of space radiation. In recent years, physical monitoring of space radiation has detected about 1 mSv per day. This value is almost 150 times higher than that on the surface of the Earth. However, the direct effects of space radiation on human health are currently unknown. Therefore, it is important to measure biological dosimetry to calculate relative biological effectiveness (RBE) for human health during long-term flight. The RBE is possibly modified by microgravity. In order to understand the exact RBE and any interaction with microgravity, the ISS centrifugation system will be a critical tool, and it is hoped that this system will be in operation as soon as possible. Key words; space, space radiation, biological effect, high-LET, ISS Characteristics of space and the composition of space radiation the radiation being composed of α-particles and heavy For several years, human beings have been particles.